MD. Endocrinologist, Department of Endocrinology and Metabolism, Şırnak State Hospital, Şırnak, Turkey.
MD. Physician, Department of Intensive Care, Şırnak State Hospital, Şırnak, Turkey.
Sao Paulo Med J. 2021 Jul-Aug;139(4):398-404. doi: 10.1590/1516-3180.2020.0722.R1.2302021.
Critical diseases usually cause hypercortisolemia via activation of the hypothalamic-pituitary-adrenal axis.
To investigate the relationship between serum total cortisol level and mortality among coronavirus disease 2019 (COVID-19) patients in the intensive care unit (ICU), at the time of their admission.
Prospective study developed in a pandemic hospital in the city of Şırnak, Turkey.
We compared the serum total cortisol levels of 285 patients (141 COVID-19-negative patients and 144 COVID-19-positive patients) followed up in the ICU.
The median cortisol level of COVID-19-positive patients was higher than that of COVID-19 negative patients (21.84 μg/dl versus 16.47 μg/dl; P < 0.001). In multivariate logistic regression analysis, mortality was associated with higher cortisol level (odds ratio: 1.20; 95% confidence interval: 1.08-1.35; P = 0.001). The cortisol cutoff point was 31 μg/dl (855 nmol/l) for predicting mortality among COVID-19-positive patients (area under the curve 0.932; sensitivity 59%; and specificity 95%). Among the COVID-19 positive patients with cortisol level ≤ 31 μg/dl (79%; 114 patients), the median survival was higher than among those with cortisol level > 31 μg/dl (21%; 30 patients) (32 days versus 19 days; log-rank test P < 0.001).
Very high cortisol levels are associated with severe illness and increased risk of death, among COVID-19 patients in the ICU.
危重病通常通过下丘脑-垂体-肾上腺轴的激活导致皮质醇增多症。
研究重症监护病房(ICU)中 COVID-19 患者入院时血清总皮质醇水平与死亡率之间的关系。
在土耳其舍尔纳克市的一家大流行医院进行的前瞻性研究。
我们比较了 285 名 ICU 患者(141 名 COVID-19 阴性患者和 144 名 COVID-19 阳性患者)的血清总皮质醇水平。
COVID-19 阳性患者的皮质醇中位数高于 COVID-19 阴性患者(21.84μg/dl 与 16.47μg/dl;P<0.001)。在多变量逻辑回归分析中,死亡率与较高的皮质醇水平相关(比值比:1.20;95%置信区间:1.08-1.35;P=0.001)。皮质醇截断值为 31μg/dl(855nmol/l),用于预测 COVID-19 阳性患者的死亡率(曲线下面积 0.932;敏感性 59%;特异性 95%)。在皮质醇水平≤31μg/dl(79%;114 例)的 COVID-19 阳性患者中,中位生存时间高于皮质醇水平>31μg/dl(21%;30 例)(32 天与 19 天;对数秩检验 P<0.001)。
在 ICU 中 COVID-19 患者中,非常高的皮质醇水平与严重疾病和死亡风险增加相关。